Significant Change in Pharmaceutical Stability Testing : Pharmaceutical Guidelines

Significant Change in Pharmaceutical Stability Testing

When the changes in results of pharmaceutical products during their stability testing are reported as significant change.
Stability of the pharmaceutical products is determined by storing the product under Accelerated and Long Term Conditions. The product is then analyzed at different time stations for any significant change in physical or chemical condition.

“Significant Change” is an important or remarkable change in any physical or chemical condition of the pharmaceutical product. These changes may occur in the product during the stability study of the drug product.

Significant ChangeAccording to ICH “significant change” for a drug product is defined as:
1. A 5% change in assay from its initial value; or failure to meet the acceptance criteria for potency when using biological or immunological procedures;
2. Any degradation product’s exceeding its acceptance criterion;
3. Failure to meet the acceptance criteria for appearance, physical attributes, and functionality test (e.g., color, phase separation, resuspendibility, caking, hardness, dose delivery per actuation); however, some changes in physical attributes (e.g., softening of suppositories, melting of creams) may be expected under accelerated conditions;
and, as appropriate for the dosage form:
4. Failure to meet the acceptance criterion for pH; or
5. Failure to meet the acceptance criteria for dissolution of 12 dosage units.

These changes in Accelerated storage conditions are considered as a significant change for drug products. For any drug substance, significant change is a failure of substance to meet the specification.

5% change in the assay is an absolute change in the initial result; it means direct 5% from the initial value. For example - if initial assay of any product is 98% then the significant change will be 93%. It will not be 5% of 98%. But if the assay is analyzed by the biological method, results below the acceptance criteria will be considered as significant change because biological methods have less accuracy and may produce fluctuated results.

Failure to meet the specification for related substances, physical appearance, moisture content, hardness, friability, solubility, pH and other similar tests is considered as a significant change in pharmaceutical substances and products.

A significant change in dissolution test is when a product fails to meet the specification in S2 stage i.e. 12 dosage units are used in the analysis.

ICH Q1E says, when gelatin capsule and gel-coated tablets fail to meet the specification of dissolution, it will not be a significant change if no other significant change is found. If phase separation of the semisolid product or liquid oral dosage forms occurs during the accelerated storage conditions, testing at intermediated storage conditions should be done.

Also see: Shelf Life Estimation of Pharmaceutical Products

View Video Tutorials





Ankur Choudhary is India's first professional pharmaceutical blogger, author and founder of Pharmaceutical Guidelines, a widely-read pharmaceutical blog since 2008. Sign-up for the free email updates for your daily dose of pharmaceutical tips.
.moc.enilediugamrahp@ofni :liamENeed Help: Ask Question


Click Here

5 comments: Post Yours! Read Comment Policy ▼

  1. all these changes are for accelerated as well as long term?

    ReplyDelete
  2. If I am doing accelerated test for a cream of tretinoin, and the pharmacopoeia monograph accept contains not less than 90 and no more that 120%. Are some change in the limit of 5% like a "significant change " in my study?
    Thanks

    ReplyDelete
  3. Very nice notes. Easily understandable. Thank you sir

    ReplyDelete
  4. Significant change observed, than what is the immediate action for example in assay or description shall we go for oos or any other explanation please kindly explain sir,

    ReplyDelete
  5. The significant change in the %assay from the time T0 to the current Time point need to evaluate while performing the ACC conditions for biological and immunological Assay test procedures.

    Is the same criteria applicable for Solid oral dosage forms testing regular Assay by HPLC method?

    Please send your comments on this.

    ReplyDelete


Follow Pharmaguideline


CURRENT JOBS

Show All ❭❭Jobs by PharmaJobs

WRITE A POWERFUL CV

Click Here



ADVERTISE HERE


GET APP FOR NEWS UPDATES

Scan to Download

Android App
Android App

Recent Posts